Charles River Laboratories International (CRL) Faces Biotech R&D Spending Headwinds

分组1 - Invesco Small Cap Value Fund reported a quarterly return of 6.79% in Q4 2025, outperforming the Russell 2000 Value Index which returned 3.26% [1] - For the full year, the fund achieved a return of 17.64%, compared to 12.59% for the Russell 2000 Value Index [1] - The fund's performance was bolstered by stock selection in the Information Technology sector, contributing approximately 2.90% to relative performance, while health care and financials detracted [1] 分组2 - Charles River Laboratories International, Inc. (NYSE:CRL) is a leading contract research organization that supports drug discovery, development, and manufacturing for pharmaceutical and biotechnology companies [3] - The stock of Charles River Laboratories had a one-month return of -2% and traded between $91.86 and $228.88 over the last 52 weeks, closing at approximately $179.58 per share with a market capitalization of about $8.86 billion [2] - Slower spending on biotech and pharma R&D has been a headwind for Charles River Laboratories, presenting an opportunity for investment at an attractive discount to intrinsic value [3] 分组3 - At the end of Q4 2025, 53 hedge fund portfolios held shares of Charles River Laboratories, an increase from 50 in the previous quarter [5] - Despite the potential of Charles River Laboratories, there is a belief that some AI stocks may offer greater promise for higher returns in a shorter time frame [5]